Cargando…
Impact of Genetic Polymorphisms and Biomarkers on the Effectiveness and Toxicity of Treatment of Chronic Myeloid Leukemia and Acute Myeloid Leukemia
Most malignant hematological diseases are generally a consequence of acquired mutations or rearrangements in cell replication processes. Acute myeloid leukemia (AML) is a clinically and molecularly heterogeneous disease that results from acquired genetic and epigenetic alterations in hematopoietic p...
Autores principales: | Alarcón-Payer, Carolina, Sánchez Suárez, María Del Mar, Martín Roldán, Alicia, Puerta Puerta, José Manuel, Jiménez Morales, Alberto |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9604625/ https://www.ncbi.nlm.nih.gov/pubmed/36294746 http://dx.doi.org/10.3390/jpm12101607 |
Ejemplares similares
-
A Real-World Evidence-Based Study of Long-Term Tyrosine Kinase Inhibitors Dose Reduction or Discontinuation in Patients with Chronic Myeloid Leukaemia
por: Martín Roldán, Alicia, et al.
Publicado: (2023) -
Arterial hypertension assessment in a population with chronic myeloid leukemia
por: Roa-Chamorro, Ricardo, et al.
Publicado: (2021) -
Stem Cell Biomarkers in Chronic Myeloid Leukemia
por: Jiang, Xiaoyan, et al.
Publicado: (2008) -
Role of Biomarkers in the Management of Acute Myeloid Leukemia
por: Small, Sara, et al.
Publicado: (2022) -
Chronic myeloid leukemia versus acute myeloid leukemia in patients with retinoblastoma
por: Leahey, Ann-Marie, et al.
Publicado: (2021)